Skip to main content

Sandra Salgado Perandres

Sóc tècnic de laboratori des de l'any 2000 i estic treballant al laboratori d´immunologia cel·lular des de l'any 2005 que vaig aconseguir la plaça en propietat.

Institutions of which they are part

Research technician
Translational Immunology
Vall Hebron Institut de Recerca
Specialist Technician
Immunology
Cross-departmental services
Sandra Salgado Perandres

Sandra Salgado Perandres

Sandra Salgado Perandres

Institutions of which they are part

Research technician
Translational Immunology
Vall Hebron Institut de Recerca
Specialist Technician
Immunology
Cross-departmental services

Sóc tècnic de laboratori des de l'any 2000 i estic treballant al laboratori d´immunologia cel·lular des de l'any 2005 que vaig aconseguir la plaça en propietat.

He treballat des de l'any 2000 fins al 2005 en diferents llocs, com àrees especials: fàrmacs, hepatitis i a les consultes de sintrom i al laboratori bàsic d'hematologia, bioquímica i coagulació. Des del 2005 estic treballant al laboratori d'immunologia cel·lular, fent el diagnòstic i seguiment d'immunodeficiències primàries i secundàries. Tinc molta experiència en la utilització de citometres de fluxe, en la realització d'ELISA i proves de cultius cel·lulars especials en campana de flux laminar.

Projects

Caracterización transcriptómica, epigenética y funcional de pacientes con síndrome hemofagocífico secundario.

IP: Mónica Martínez Gallo
Collaborators: Gemma Vila Pijoan, Sandra Salgado Perandres, Adolfo Ruiz Sanmartin, Montserrat Pujol Jover, Estefania Moreno Ruzafa, Jacques Gabriel Rivière
Funding agency: Instituto de Salud Carlos III
Funding: 117370
Reference: PI18/00346
Duration: 01/01/2019 - 30/06/2023

Related news

The new technology allows more sensitive detection of scleroderma patients' autoantibodies, which are related to the severity and progression of the disease.

A study from the Vall d’Hebron Campus demonstrates that the Ex Vivo C5b-9 deposition test is useful for monitoring the activity of the complement system (CS) in patients with aHUS or transplant-associated TMA.

The results show that, in some patients with mutations in the X chromosome, the healthy gene is inactivated and the mutated gene manifests itself, which favors the onset of the disease.

Related professionals

María Viñas I Casas

María Viñas I Casas

Predoctoral researcher
Protein kinases in cancer research
Read more
Alvaro Calabuig Goena

Alvaro Calabuig Goena

Postdoctoral researcher
Cardiovascular Diseases
Read more
Raquel Rodríguez Gil

Raquel Rodríguez Gil

Main researcher
Multidisciplinary Nursing Research Group
Read more
Alba González Robles

Alba González Robles

Predoctoral researcher
Infectious Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.